Live Breaking News & Updates on Interchangeable Biosimilars

Stay updated with breaking news from Interchangeable biosimilars. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Challenges Payers Face With Biosimilars

Kimberly C. Chen DO, MSHLM, and Maia Kayal, MD, MS, review the challenges related to biosimilars from the payer perspective and strategies payers may employ to help improve the uptake of biosimilars. ....

Maia Kayal , Kimberlyc Chen , Biosimilars Stakeholder Summit , Interchangeable Biosimilars , Inflammatory Diseases , Challenges With Biosimilars , Payer Perspective , Improve Biosimilar Uptake , Biosimilar Extrapolation , Reduced Approval Time , Multiple Indications , Reference Product , Fda Approval Process ,

Barriers to Biologics Access

Jonathan Kay, MD, reviews the barriers related to access of biologics such as economic barriers, health inequities, or disparities. ....

Jonathan Kay , Biosimilars Stakeholder Summit , Interchangeable Biosimilars , Inflammatory Diseases ,

Savings Potential With Biosimilars

Jonathan Kay, MD, and Kimberly C. Chen DO, MSHLM, define what a biosimilar is and discuss the potential for a lower cost than the reference product. ....

Jonathan Kay , Kimberlyc Chen , Biosimilars Stakeholder Summit , Interchangeable Biosimilars , Inflammatory Diseases , Reference Product , Lower Cost , Clinical Trial ,

Cost Drivers Contributing to the Economic Impact of Inflammatory Diseases

A panel of experts review the key drivers contributing to the economic impact of inflammatory diseases in the United States.

....

United States , Biosimilars Stakeholder Summit , Interchangeable Biosimilars , Inflammatory Diseases , Drivers Contributing , Economic Impact ,

Biologics Used in Inflammatory Diseases

Maia Kayal, MD, MS, provides an overview of the biologics used in inflammatory diseases. ....

Maia Kayal , Biosimilars Stakeholder Summit , Interchangeable Biosimilars , Inflammatory Diseases ,